University of Heidelberg, DOASENSE GmbH, Waldhofer Str. 102, 69123 Heidelberg, Germany.
Department of Haematology, Sydney Centres for Thrombosis and Haemostasis, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.
Clin Chem Lab Med. 2020 Jun 25;58(7):1029-1036. doi: 10.1515/cclm-2020-0502.
The timely and accurate diagnosis of infection with severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), remains the cornerstone of efforts to provide appropriated treatment for patients, to limit further spread of the virus and ultimately to eliminate the virus from the human society. We focus this article on (a) developments for improvement of diagnosis of specific SARS-CoV-2 virus, (b) laboratory changes in the immunologic and coagulation system, (c) therapeutic options for anticoagulant treatment of seriously affected patients and (d) on the perspectives through improvement of diagnostic and therapeutic medical procedures.
及时准确地诊断严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染，这是导致 2019 年冠状病毒病（COVID-19）的原因，仍然是为患者提供适当治疗、限制病毒进一步传播并最终从人类社会消除病毒的努力的基石。我们专注于以下几个方面：（a）改进针对特定 SARS-CoV-2 病毒的诊断方法的进展，（b）免疫系统和凝血系统的实验室变化，（c）严重感染患者抗凝治疗的治疗选择，以及（d）通过改进诊断和治疗医疗程序的观点。
